# Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

> **NCT03188159** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 36 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT03188159
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2018-03-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03188159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03188159, "Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03188159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*